Document:

exv10w13wxay

 

EXHIBIT 10.13(a)

EXHIBIT A

DIGENE CORPORATION

AMENDMENT TO THE AMENDED AND RESTATED 1999 INCENTIVE PLAN

Equity Incentive Awards to Employees Working in France

	1.	 	Purpose of this Amendment.

     The purpose of this Amendment (the “French Sub-Plan”) to the Amended and Restated 1999
Incentive Plan, as amended (the “Plan”) of Digene Corporation (the “Company”), is to enable the
Company to grant to Employees, working in France, either temporarily or permanently and employed by
either the Company or any Subsidiary, or working for the Company or any Subsidiary and residing in
France (the “French Employees”), Stock Options and Restricted Stock Unit Awards under the Plan in a
manner consistent with applicable law. Without limiting the foregoing, as of and after the date
this French Sub-Plan, as amended, is adopted and approved by the Committee, the Stock Options and
Restricted Stock Unit awards granted to French Employees under this French Sub-Plan are intended to
qualify under Sections L. 225-177 to L. 225-186 of the French commercial code to benefit from both
preferential tax treatment and an exemption from social charges.

     Unless otherwise defined herein, the capitalized terms used in this French Sub-Plan shall have
the meanings set forth in the Plan.

     In the event of a conflict between the provisions of the Plan and this French Sub-Plan with
respect to Awards granted to any French Employee, the provisions of this French Sub-Plan shall
control. Except as amended by this French Sub-Plan, the Plan shall continue in full force and
effect.

	2.	 	Provisions Specific to Awards to French Employees.

	 	(a)	 	Eligible Participants.

     (i) The Participants eligible to receive Stock Option Awards and Restricted Stock Unit
Awards under this French Sub-Plan include the French Employees, including any director or
manager having a management function in France for the Company or any Subsidiary organized
under French law; provided, however, that if any such Participant is subject to U.S. federal
tax laws at the time of the proposed Award, such Participant shall not be eligible for
Awards under this French Sub-Plan at such time. No other Participants under the Plan or
independent contractors or consultants to the Company or any of its Subsidiaries are
eligible to receive Stock Option Awards or Restricted Stock Unit Awards under this French
Sub-Plan.

     (ii) Neither Stock Options nor Restricted Stock Unit Awards shall be granted under this
French Sub-Plan to any French Employee who holds shares representing 10% or more of the
Company’s outstanding common stock at the time of the Award.

     (b) Eligible Subsidiary. In the event of any future change to the definition of
Subsidiary under the Plan, French Employees who receive Stock Options issued by the Company or
Restricted Stock Units awarded by the Company must be employed by a company with sufficiently close
capital links to the Company, therefore, at least 10% of the French Employee’s

 

 

employer company’s
capital must be held, directly or indirectly, by the Company (or the employer company must directly
or indirectly hold at least 10% of the Company’s capital) or at least 50% of the employer’s company
capital must be held, directly or indirectly, by a company which holds, directly or indirectly, at
least 50% of the Company’s capital.

     (c) Exercise Price of Stock Options.

     (i) The exercise price at the time of the grant of any Stock Option granted to a French
Employee under this French Sub-Plan shall be the Fair Market Value on the Date of Grant. If
such exercise price is no less than 80% of the average Fair Market Value of the Common Stock
during the 20 trading days preceding the Award, or 80% of the average repurchase price of
the shares of Common Stock held by the Company (if the Company elects to grant Stock Options
based on authorized and issued shares reacquired by the Company and allocated to cover the
Stock Option Award to a French Employee), then such Award will be “qualified” for French law
purposes under this French Sub-Plan.

     (ii) Notwithstanding any other provision of the Plan, including, without limitation,
Section 4.3 (Changes) and Section 6.4(j) (Merger and Other Fundamental Transactions), the
exercise price of any Stock Option granted to a French Employee under this French Sub-Plan
is fixed as of the date of grant and shall be adjusted only upon the occurrence of an event
specified under the French commercial code (Section L. 225-181).

     (d) Restrictions on Granting of Awards. Notwithstanding any other provision of the
Plan or applicable law, no Stock Option Awards or Restricted Stock Unit Awards shall be made to any
French Employee under this French Sub-Plan:

     (i) within twenty (20) trading days following a distribution of dividends or a capital
increase of the Company (with trading days meaning trading on the principal stock exchange
on which the Company’s Common Stock is then listed);

     (ii) during the ten (10) trading days preceding and following the filing, with the U.S.
Securities and Exchange Commission, of the Company’s Annual Report on Form 10-K or any
Quarterly Report on Form 10-Q (or any successor form to either the Form 10-K or Form 10-Q);
or

     (iii) during a period starting on the date that the Company becomes aware of
information which could have a significant impact on the Company’s Common Stock price and
ending ten (10) trading days after this information has been made public in compliance with
applicable law. The Committee shall have the authority to make the determination called for
by this Section 2(d)(iii) at the time of any applicable Award.

     (e) Holding Period. Each Stock Option Award to a French Employee under this French
Sub-Plan shall provide that either: (i) the Stock Options shall not begin to vest until the date
four (4) years after the Date of Grant; or (ii) the Optionee shall be entitled to exercise all or a
portion of the Stock Option Award in accordance with the vesting schedule, but shall not be
entitled to sell the underlying Common Stock until at least four (4) years after the Date of Grant.
Each Restricted Stock Unit Award to a French Employee under this French Sub-Plan shall provide:

2

 

(1) a minimum vesting schedule of two (2) years after the Date of Grant; and (2) a mandatory two
(2) year holding period on the Shares received on the vesting date.

     (f) Death or Disability of French Employee. In the event of the death of a French
Employee with outstanding Stock Options at the time of his or her death, the Stock Options may be
exercised at any time during a maximum six (6) month period following the date of the French
Employee’s death by the French Employee’s estate or by a person who acquired the right to exercise
the Stock Option by request or inheritance, but only to the extent that the French Employee was
entitled to exercise the Stock Options at the date of death or would have been entitled to exercise
the Stock Options during the said maximum six (6) month period. If the successors do not exercise
the Stock Options granted to such French Employee during such six-month period, the successors’
rights in respect of such Stock Options shall lapse in total without any formality and the shares
of Common Stock underlying such Stock Options shall revert to the Plan. This provision
specifically alters the provisions of Section 6.4(f) (Death) of the Plan as related to Stock Option
Awards to French Employees under this French Sub-Plan.

          In the event of the Disability of a French Employee prior to the vesting of any Restricted
Stock Unit Award, the forfeiture restrictions shall lapse as set forth in Section 8.2(d) of the
Plan; provided, that the Company shall retain the certificate representing the then-vested Shares
for the benefit of the French Employee until at least two full years have elapsed since the Date of
Grant; and the French Employee must thereafter comply with the additional two-year holding period
described in Paragraph 2(e) of this French Sub-Plan, after delivery of the certificate from the
Company, with respect to any such Restricted Stock Unit Awards. This provision specifically alters
the provision of Section 8.2(d) (Termination of Employment) of the Plan as related to Restricted
Stock Unit Awards to French Employees under this French Sub-Plan.

     (g) Size of Award. No more than one-third of the Company’s outstanding Common Stock
may be subject to Stock Options Awards and Restricted Stock Unit Awards under this French Sub-Plan
at any time during the term of the Plan.

     (h) Restrictions on Requirement to Hold Common Stock after Exercise. The Committee
shall not grant a Stock Option, or amend an existing Stock Option Award, to any French Employee
under this French Sub-Plan that requires the French Employee to hold the shares of Common Stock for
more than three (3) years after exercise of the Stock Option Award.

	3.	 	Approval of this French Sub-Plan.

     This French Sub-Plan, as amended, was approved and adopted by the Committee on July 26, 2006
in accordance with the provisions of Sections 3.2 (Awards) and 9.1 (Termination or Amendment of the
Plan) of the Plan.

As revised by the Compensation Committee by unanimous written consent, dated March 2, 2005, to
add Exhibit A to provide for additional restrictions and requirements related to the issuance of
stock option awards to eligible French Employees.

As revised by the Compensation Committee at its meeting on July 26, 2006, to amend and restate this
Exhibit A — Equity Incentive Awards to Employees Working in France to add restricted stock units to
the types of awards that can be granted to eligible French Employees.

3exv10w23

 

EXHIBIT 10.23

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH “*” AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.

NONEXCLUSIVE SUBLICENSE

AGREEMENT UNDER THE CASKEY PATENTS

THIS NONEXCLUSIVE SUBLICENSE AGREEMENT (the “Agreement”) is made and is effective the thirtieth
(30th) day of June 2006 (the “Effective Date”) by and between Digene Corporation (“DIGENE”), a
Delaware corporation with its principal place of business at 1201 Clopper Road, Gaithersburg, MD
20878, and Abbott Laboratories (“ABBOTT”), an Illinois corporation having its principal place of
business at 100 Abbott Park Road, Abbott Park, IL, 60064 USA

WITNESSETH:

RECITALS

WHEREAS, United States patent No. 5,582,989 and foreign counterparts thereto (the “Caskey Patents)
generally disclose and claim certain inventions generally characterized as Multiple Genomic DNA
Amplification for Deletion Detection;

WHEREAS, ABBOTT holds an exclusive license with the right to grant sublicenses under the Caskey
Patents from the Baylor College of Medicine (“BAYLOR”);

WHEREAS, DIGENE is in the business of developing, manufacturing and selling diagnostic products;
and

WHEREAS, ABBOTT and DIGENE have agreed to enter into a sublicense agreement with respect to the
Caskey Patents, on the terms and conditions set forth herein,

DIGENE and ABBOTT agree hereto as follows:

1. DEFINITIONS

     1.1 “Affiliate” of a party shall mean any other person or entity that at the relevant
time directly or indirectly controls, is controlled by, or is under common control with such party
through the ownership or control, directly or indirectly, of more than 50% of all the voting power
of the shares or other interests entitled to vote for the election of directors or other governing
authority or otherwise having the power to govern the financial and operating policies or to
appoint the management of an organization.

     1.2 “Caskey Patents” shall mean United States Patent No. 5,582,989 by Caskey, et al.,
as described above, and foreign counterparts thereto, continuations, continuations in part that
Abbott has the right and power to grant a sublicense to such continuation in part, divisionals,
reissues, and reexaminations thereof and patents and patent applications claiming priority
therefrom, including, without limitation, the patents listed in Exhibit 1 and incorporated herein
by reference.

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH “*” AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.

     1.3 “Field” shall mean human in vitro diagnostics.

     1.4 “First Commercial Sale” shall mean the first time DIGENE transfers Licensed
Product to an independent third party or performs a Licensed Process for monetary consideration.

     1.5 “Indemnitee” shall mean:

	 	(a)	 	ABBOTT, its directors, officers, employees and agents; and
	 
	 	(b)	 	BAYLOR, the Howard Hughes Medical Institute, their officers,
employees and agents, and the inventors of the Caskey patents.

     1.6 “Licensed Process” shall mean any process that would constitute, but for the
sublicense granted herein, an infringement of any Valid Claim within the Caskey Patents.

     1.7 “Licensed Product” shall mean any product which, the making, using, selling,
offering for sale or importing of which, would constitute, but for the sublicense granted herein,
an infringement of any Valid Claim within the Caskey Patents.

     1.8 “Valid Claim” shall mean an issued claim of the Caskey Patents which has not been
ruled invalid by a court or an administrative agency of competent jurisdiction from which all
appeals have been exhausted.

2. GRANT

     2.1 Subject to the terms and conditions of this Agreement, ABBOTT hereby grants to DIGENE a
fully paid-up worldwide, nonexclusive, irrevocable, nontransferable sublicense without the right to
sublicense, to make, have made, use, offer for sale, sell, have sold, and import Licensed Products
and Licensed Processes for use in the Field. The sublicense and right granted to DIGENE shall
extend to any and all DIGENE Affiliates.

     2.2 The right to sell Licensed Product granted herein shall extend to DIGENE Distributors
relative to the distribution of Licensed Products from their respective DIGENE supplier. The right
to use Licensed Products shall extend to DIGENE’s end-user customers.

3. FEES

     3.1 In consideration for the sublicenses, releases and rights granted herein, DIGENE agrees to
pay to ABBOTT or its designee the non-refundable sum of Three Million Five Hundred Thousand U.S.
Dollars ($3,500,000) payable as follows:

	 	(a)	 	One Million U.S. Dollars ($1,000,000) within thirty (30) days
of the Effective Date of this Agreement;

-2-

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH “*” AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.

	 	(b)	 	One Million Two Hundred Fifty Thousand U.S. Dollars
($1,250,000) on or before December 31, 2006; and
	 
	 	(c)	 	One Million Two Hundred Fifty Thousand U.S. Dollars
($1,250,000) on or before July 1, 2007.

     3.2 DIGENE agrees that the fee specified in paragraph 3.1 herein, is a single fee for the paid
up sublicense granted in paragraph 2.1, and that the fee is due and owing in the manner specified
as of the Effective Date, and any subsequent decision by DIGENE to exercise its rights under the
sublicense or not exercise its rights as the case may be, or any change in the status of the Caskey
Patents shall have no effect on DIGENE’s continuing obligation to pay the fee and make the payments
specified in paragraph 3.1.

     3.3 DIGENE agrees to pay to ABBOTT or its designee the non-refundable sum of [***********]
U.S. Dollars ($[*******]) within sixty (60) days of the First Commercial Sale of a Licensed Product
or a Licensed Process directed to the detection of any human papilloma virus (HPV). DIGENE shall
notify ABBOTT promptly following its First Commercial Sale of a Licensed Product or a Licensed
Process directed to the detection of any HPV.

     3.4 All payments due ABBOTT shall be made in U.S. Dollars by wire transfer to:

Bank Name: [*****]

SWIFT Code: [****]

ABA#: [*****]

Beneficiary Name: [*****]

Beneficiary Acct ID: [****]

Ref: Digene/Abbott Molecular Sublicense to Caskey Patents

or as ABBOTT may designate in a notice to DIGENE.

4. TERM AND TERMINATION

     4.1 Unless otherwise terminated by operation of law or by acts of the parties in accordance
with the terms of this Agreement, this Agreement shall be in force from the Effective Date and
shall remain in effect for the life of the Caskey Patents (i.e., until all of the Caskey
Patents have expired). ABBOTT shall provide prompt written notice to DIGENE upon any earlier
expiration or termination of any of the Caskey Patents than indicated in Exhibit 1.

     4.2 Any termination of this Agreement shall not affect

	 	(a)	 	A party’s obligations which have accrued prior to termination;
	 
	 	(b)	 	DIGENE’s continuing obligation to indemnify the Indemnitees in
accordance with Article 7; and

-3-

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH “*” AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.

	 	(c)	 	The parties’ continuing obligation to maintain the
confidentiality of the terms of this Agreement.

     4.3 Should either party violate or fail to perform any material term or covenant of this
Agreement, the non-defaulting party may give written notice of such default to the defaulting
party. The parties shall then resolve the dispute and alleged default in accordance with Section
12.6 herein.

     4.4 ABBOTT shall have the right to terminate this Agreement and the sublicense and rights and
covenants granted herein in the event that DIGENE initiates any suit, reexamination, nullity
action, opposition to grant or other legal action seeking to invalidate any claims of a Caskey
Patent or supports any of the foregoing actions.

5. LIMITED WARRANTY

     5.1 ABBOTT represents and warrants that it is the exclusive licensee of the Caskey Patents and
has all lawful rights and powers necessary to enter into this Agreement and to grant the
sublicenses and rights granted hereunder. ABBOTT further represents and warrants that this
Agreement will be assigned to BAYLOR and BAYLOR will respect its terms in the event ABBOTT loses
its exclusive license and the right to grant the sublicenses and rights granted hereunder.

     5.2 The sublicenses and rights granted herein are provided WITHOUT WARRANTY OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. EXCEPT AS TO THE
CASKEY PATENTS SUBLICENSED HEREUNDER, ABBOTT MAKES NO REPRESENTATION OR WARRANTY THAT THE LICENSED
PRODUCTS OR LICENSED PROCESSES WILL NOT INFRINGE ANY PATENT, OTHER THAN THE CASKEY PATENTS, OR
OTHER PROPRIETARY RIGHT.

     5.3 IN NO EVENT WILL ABBOTT BE LIABLE FOR ANY INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES
RESULTING FROM DIGENE’S EXERCISE OF THIS SUBL1CENSE OR USE OF LICENSED PRODUCTS.

6. PATENT MARKING

     6.1 DIGENE agrees to mark all Licensed Products made, used or sold under the terms of this
Agreement, or their containers, with the applicable patent numbers listed in Exhibit 1.

     6.2 DIGENE agrees to cause its Affiliates to mark all Licensed Products made, used or sold
under the terms of this Agreement, or their containers as feasible with the applicable patent
number of any applicable Caskey Patents practiced thereby.

-4-

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH “*” AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.

7. INDEMNIFICATION

     7.1 DIGENE will indemnify, hold harmless and defend Indemnitees against any and all claims,
causes of action, suits, proceedings, losses, damages, demands, fees, expenses, fines, penalties
and costs (including reasonable attorney’s fees) (“Claims”) arising out of, relating to or in
connection with any third party action which result from or arise out of DIGENE’s exercise of the
sublicense and rights granted herein including any sale, manufacture or use of a Licensed Product
or Licensed Process. This indemnification will include, but not be limited to, any product
liability.

     7.2 ABBOTT shall promptly notify DIGENE in writing of any Claim which ABBOTT believes it may
have a right of indemnification under this Agreement. ABBOTT will provide reasonable cooperation
to DIGENE for any Claim for which DIGENE is indemnifying and holding ABBOTT harmless.

     7.3 Abbott shall indemnify, defend and hold DIGENE and its Affiliates and their officers,
directors, employees, and representatives harmless from and against any and all Claims arising out
of, relating to or in connection with any third party action against DIGENE for infringement of the
Caskey Patents,

     7.4 DIGENE shall promptly notify ABBOTT in writing of any Claim which DIGENE believes it may
have a right of indemnification under this Agreement. DIGENE will provide reasonable cooperation
to ABBOTT for any Claim for which ABBOTT is indemnifying and holding DIGENE harmless.

8. NOTICES

     8.1 Any notice or payment required to be given to either party shall be deemed to have been
properly given and to be effective (a) on the date of delivery if delivered in person or by
facsimile or (b) five (5) days after mailing by first-class certified mail, postage paid, to the
respective addresses identified below; or to such other address as the applicable party shall
designate by written notice to the other party.

	 	 	 	 	 
	 

	 	If to Abbott:
	 	Abbott Molecular Inc.
	 

	 	 	 	1300 East Touhy Avenue
	 

	 	 	 	Des Plaines, IL 60018
	 

	 	 	 	Attention: Director of Licensing and Business Development
	 

	 	 	 	Facsimile Number: 224.361.7054

-5-

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH “*” AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.

	 	 	 	 	 
	 

	 	With a copy to:
	 	Abbott Laboratories
	 

	 	 	 	Dept. 322, Bldg. AP6A/2
	 

	 	 	 	100 Abbott Park Road
	 

	 	 	 	Abbott Park, IL 0064-6049
	 

	 	 	 	Attention: Divisional Vice President,
	 

	 	 	 	Medical Products Group Legal Operations

	 

	 	 	 	Facsimile Number: 847.938.1206
	 
	 	 	 	 
	 

	 	If to DIGENE:
	 	Digene Corporation
	 

	 	 	 	Chief Executive Officer
	 

	 	 	 	1201 Clopper Road
	 

	 	 	 	Gaithersburg, Maryland 20878
	 

	 	 	 	Facsimile Number: 301.944.7017
	 
	 	 	 	 
	 

	 	With a copy to:
	 	Digene Corporation
	 

	 	 	 	Senior Vice President, General Counsel and Secretary
	 

	 	 	 	1201 Clopper Road
	 

	 	 	 	Gaithersburg, MD 20878
	 

	 	 	 	Facsimile Number: 240.632.7406

9. ASSIGNMENT

     9.1 This Agreement is binding upon and shall inure to the benefit of ABBOTT, its successors
and assigns, but shall be personal to DIGENE. The sublicenses and rights granted herein to DIGENE
are not assignable by them except in whole to:

	 	(a)	 	A bona fide purchaser of DIGENE as a result of a merger or
acquisition or asset purchase or of any of its Affiliates to which the
sublicense and rights pertain, provided that such bona fide purchaser agrees to
the terms and conditions of this Agreement; and
	 
	 	(b)	 	A wholly owned Affiliate of DIGENE.

10. GOVERNING LAW

     10.1 The Agreement and its construction are subject to the laws of the State of Illinois with
the exception of any choice of law provisions.

11. CONFIDENTIALITY

     11.1 Except as required by law, the terms of this Agreement and all information disclosed to
one party by another party and designated as confidential information by the producing party shall
be considered as confidential information of the producing party and the

-6-

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH “*” AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.

party receiving such
information shall use the same care to protect such information as it uses to protect its own
information of like kind. Neither party will use or disclose the terms and conditions of this
Agreement to any third party in any form whatsoever, without the express prior written consent of
the other party, except that ABBOTT will be permitted to disclose the Agreement and its terms to
BAYLOR. In disclosing the Agreement and its terms to BAYLOR, however, ABBOTT shall impose the same
requirements of confidentiality on BAYLOR as set forth in this paragraph.

12. MISCELLANEOUS

     12.1 Entire Agreement. This Agreement contains the entire understanding of the
parties with regard to the matters set forth in this Agreement and shall supercede all previous
communications, representations or understandings either oral or written, between the parties
relating to the subject matter hereof.

     12.2 Amendment or Modification. No Party shall claim any amendment, modification or
release from any provision hereof by mutual agreement, unless in writing signed by an authorized
representative of each Party and under no circumstances shall a Party claim any amendment,
modification or release from any provision of this Agreement by virtue of a Party signing or
complying with the terms of the other Party’s purchase order or order acknowledgment forms or
failing to object to any term or condition that is contained in any such forms.

     12.3 Survivability. In case any of the provisions contained in this Agreement shall
be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or
unenforceability shall not affect any other provisions hereof and this Agreement shall be construed
as if such invalid or illegal or unenforceable provisions had never been contained herein.

     12.4 Counterparts. This Agreement may be executed in duplicate originals at the
convenience of the parties.

     12.5 Public Announcements. No Party shall make any public announcement or other
disclosure concerning the transactions contemplated herein, or make any public statement which
includes the name of the other Party or any of its Affiliates, or otherwise use the name of another
Party or any of its Affiliates in any public statement or document, except as may be required by
regulatory authority, law or judicial order (and then only following consultation with the other
Party), without the prior written consent of the other Party.

     12.6 Dispute Resolution. DIGENE and ABBOTT shall first employ reasonable efforts to
resolve controversies or disputes between them arising out of or relating to this Agreement
before resorting to alternative dispute resolution process. Any remaining controversy or
claim arising out of or relating to this Agreement, or the breach thereof, shall be resolved
through the process and rules for alternative dispute resolution described in the attached Exhibit
2, which is incorporated herein by reference. The venue for any such arbitration proceeding shall
be New York, New York.

-7-

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH “*” AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.

IN WITNESS WHEREOF ABBOTT and DIGENE have executed this Agreement by their respective officers
hereunto duly authorized on the day and year written below.

	 	 	 	 	 	 	 
	ABBOTT LABORATORIES	 	DIGENE CORPORATION
	 
	 	 	 	 	 	 
	By:

	 	/s/ Edward L. Michael
	 	By:
	 	/s/ Evan Jones
	 

	 	 
	 	 	 	 
	 

	 	Edward L. Michael
	 	 	 	Evan Jones
	 

	 	President, Abbott Molecular
	 	 	 	Chief Executive Officer and
	 

	 	 	 	 	 	Chairman
	 
	 	 	 	 	 	 
	Date: 6/28/06	 	Date: 6/29/06

-8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}]]